Pharmaceutical company
Appears in 11 stories · Last updated Nov 2, 2026
Maker of deucravacitinib, the only approved TYK2 inhibitor and nomelcitinib's head-to-head comparator
InventisBio said on Nov. 2, 2026 that nomelcitinib met the main and secondary goals of a 391-patient Phase III trial in moderate-to-severe plaque psoriasis. More than 70% of patients on either of two doses reached PASI 90 at week 16, meaning their severity score fell at least 90% from baseline, and more than 80% were rated clear or almost clear. Both results beat placebo with p<0.0001, though the company has not disclosed the placebo rate.
Updated Nov 2
Partner on pumitamig, BioNTech's bispecific cancer drug
BioNTech's mRNA cancer drug BNT113, added to Merck's Keytruda, did not hold off HPV16-positive head and neck cancer longer than Keytruda alone. The miss, reported Oct. 13, was the first of the Phase 2/3 AHEAD-MERIT trial's two main goals, and US-listed BioNTech shares fell about 7% that day.
Updated Oct 30
Manufacturer of nivolumab (Opdivo), the anti-PD-1 drug tested with and without HBI-8000 in the trial
Adding an oral histone deacetylase (HDAC) inhibitor to nivolumab cut the risk of melanoma progression or death by 27% in a 404-patient Phase 3 trial. Median progression-free survival was 11.7 months with the combination and 7.4 months with nivolumab alone, according to results presented at the European Society for Medical Oncology congress in Madrid.
Developing admilparant, a potential first-in-class LPA1 receptor antagonist for IPF
Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a Phase 3 trial, but only at the lower of two tested doses. The 60 milligram dose slowed lung function decline in patients with idiopathic pulmonary fibrosis, while the 120 milligram dose fell short of statistical significance.
Updated Oct 29
As of September 2026: Paused autoimmune CAR-T trials over reversible inflammatory events
Novartis paused its autoimmune CAR-T trials this month after three patients died from a severe immune reaction, and Bristol Myers paused its own over similar inflammatory events. The same week, Kyverna Therapeutics released 12 months of follow-up data on miv-cel, its rival therapy, reporting sustained improvement in stiff person syndrome patients with no high-grade immune toxicity.
Updated Sep 24
As of September 2026: Anchor tenant at Campus Point
A venue called The Alexandria at 4150 Campus Point Court in San Diego applied for a California liquor license. The application appeared on the state's ABC licensing list on September 18, 2026.
Updated Sep 18
As of September 2026: Licensor of five immunology programs to Beeline; equity investor
Beeline Medicines' afimetoran, a once-daily oral pill for lupus, met its primary endpoint in a Phase 2 trial. The result moves the biotech into Phase 3 (pivotal) development for two forms of the disease.
Updated Sep 9
As of May 2026: Maker of competing oral psoriasis drug Sotyktu, which ICOTYDE outperformed in head-to-head trials
For two decades, treating moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions many patients refused or abandoned. On March 18, 2026, the FDA approved ICOTYDE, a once-daily pill that blocks the IL-23 receptor like injectable biologics. In trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of placebo.
Updated May 30
As of May 2026: Awaiting FDA decision on Sotyktu expansion into psoriatic arthritis
For most of the past decade, people with psoriatic arthritis who wanted a pill had one real choice: Janus kinase (JAK) inhibitors. The FDA slapped those drugs with its strongest safety warning in 2021, after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death.
As of May 2026: Building real-world evidence for Cobenfy; planning UK launch in 2026
The FDA approved Cobenfy for schizophrenia in September 2024—the first drug to treat the condition through muscarinic receptors rather than dopamine, a different approach than any approved in the previous 50 years. Bysanti (milsaperidone) followed in February 2026, cleared for both schizophrenia and bipolar I disorder. For the roughly 7 million Americans with these conditions, the treatment menu is wider than it was two years ago.
Updated May 29
As of May 2026: Incumbent oral TYK2 competitor via Sotyktu; a key benchmark for Takeda
Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).
Updated May 15
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
